Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Janne is the Director of the Lowe Center for Thoracic Oncology, the Director of the Belfer Center for Applied Cancer Science and the Director of the Chen-Huang Center for EGFR Mutant Lung Cancers.  He is a Senior Physician at Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School.  

 

2020 TTF AM SESSION - JANNE - Insights Into Acquired Resistance: the Role of Repeat Biopsies
dbrock
2020 Targeted Therapies Patient Forum AM Session - Dr. Pasi Janne - Insights Into Acquired Resistance and the Role of Repeat Biopsies
Author
Pasi Janne, MD, PhD GRACE Faculty
Image
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

Access to the full agenda can be found here: https://drive.google.com/file/d/10sk1Are37fCIHcc6laD6lh9m_DjLF1ZX/view?u....

Full bios for attending faculty can be found here: https://docs.google.com/document/d/1EQEmBpOI-vNIywsFPEIhizql_Xnzjcf5-mua....

 
In this video from the AM Session of the event, Dr. Pasi Janne examines insights into acquired resistance and the role of repeat biopsies.

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on